The Inaugural UCLA Kidney-Liver Connection Symposium

We are planning the inaugural UCLA Kidney–Liver Disease Symposium, an interdisciplinary educational forum focused on the growing clinical intersection between hepatic and renal disorders. The strong bidirectional relationship between liver and kidney disease has long been recognized, most notably in hepatorenal syndrome—a devastating complication of decompensated cirrhosis associated with exceedingly high short- and intermediate-term mortality. Despite recent therapeutic advances, outcomes remain poor, underscoring the critical need for continued education to support healthcare professionals in evidence-based management. This symposium will convene experts in nephrology, hepatology, transplant nephrology, and interventional radiology to provide state-of-the-art perspectives on hepatorenal syndrome and other complex conditions affecting both organ systems, with the goal of enhancing clinical knowledge and improving patient outcomes.

Registration Fees 

In-person & Virtual Attendance

• $100 Physicians
• $75 Allied Health Professionals

UC Recharge Payment Information
Registration payment can be submitted via the Interdepartmental or Intercampus recharge system.
For more details, please refer to document here: Recharge Information

Refunds
Cancellations must be received via email to ccpd@mednet.ucla.edu by Sunday, June 28, 2026 and will be subject to a $50 processing fee. No refunds will be granted after that date. David Geffen School of Medicine at UCLA reserves the right to cancel or postpone this course if necessary; in the event of cancellation, course fees will be fully refunded to the original form of payment. We are not responsible for other costs, such as non-refundable airline tickets or hotel penalties. 

Course Recording
The course will not be recorded.

Target Audience

Specialties - Critical Care Medicine, Internal Medicine, Nephrology, Transplant Hepatology

Professions - Fellow, Industry Representative, Nurse, Nurse Anesthetists, Pharmacist, Physician, Physician Assistant, Resident

Objectives

At the conclusion of this activity, learners will be able to:

1. Analyze the pathophysiology, epidemiology, classification, and prognostic implications of hepatorenal syndrome to support earlier recognition, risk stratification, and evidence-based diagnosis.
2. Evaluate evidence-based therapeutic strategies for hepatorenal syndrome–acute kidney injury (HRS-AKI), including vasoconstrictor therapy, albumin optimization, transjugular intrahepatic portosystemic shunt (TIPS), transplantation approaches, and supportive care, through review of clinical trial data, patient selection considerations, safety considerations, limitations of existing evidence, and practical application in routine care.
3. Compare current national and international guideline recommendations and evaluate areas of ongoing controversy and emerging evidence in hepatorenal syndrome management.
4. Recognize additional kidney–liver interactions, including metabolic dysfunction-associated steatotic liver disease (MASLD), hyponatremia in cirrhosis, and liver-associated glomerular disease, highlighting diagnostic and management challenges that require multidisciplinary care and individualized clinical decision-making.
5. Develop multidisciplinary care strategies across hepatology, nephrology, transplant medicine, critical care, and interventional radiology to improve coordination of care and consistency of evidence-based management.
6. Evaluate strategies to reduce delays in diagnosis and treatment of hepatorenal syndrome–acute kidney injury (HRS-AKI) with the goal of improving patient outcomes, including renal recovery, timely transplant evaluation, and survival.
7. Evaluate real-world clinical challenges in kidney–liver disease through multidisciplinary case-based discussion with faculty experts to identify strategies that support collaboration, innovation, and evidence-based patient care.

Accreditation

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved by the AMA PRA Category 1 Credits™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.